<DOC>
	<DOCNO>NCT02689271</DOCNO>
	<brief_summary>To enable paradigm mp-MRI biopsy patient suspected prostate cancer well select patient benefit diagnostic MRI improve performance mp-MRI</brief_summary>
	<brief_title>CombIning advaNces imagiNg With biOmarkers improVed Diagnosis Aggressive prosTate cancEr</brief_title>
	<detailed_description>Patients undergo advance diffusion-weighted MRI sequence call VERDICT intention well characterise prostate cancer . A panel serum urine biomarkers also analyse , hope predict patient go positive MRI . OBJECTIVES : - To establish fluidic marker - prostate MRI paradigm : ( ) utilise fluidic marker rationalise selection patient significant prostate cancer ; ( ii ) improve diagnostic accuracy image standard multiparametric ( mp ) MRI - Enable pathway rapid clinical evaluation emerge fluidic marker exosomes - Assess repeatability VERDICT MRI - Ascertain whether VERDICT derive quantitative parameter correlate quantitative histological parameter - Develop database fluidic marker VERDICT characterise , mp-MRI , histologically validated patient subsequent exploratory longitudinal outcome analysis</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<criteria>Men refer UCLH prostate mpMRI follow biopsy elsewhere biopsy naive men present UCLH clinical suspicion prostate cancer . Men unable MRI scan , artefact would reduce quality MRI Men unable give informed consent Previous treatment ( prostatectomy , radiotherapy , brachytherapy ) prostate cancer Ongoing hormonal treatment prostate cancer Previous biopsy within 6 month schedule mpMRI</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>MRI</keyword>
	<keyword>Magnetic resonance imaging</keyword>
	<keyword>Biomarkers</keyword>
	<keyword>Fluidics</keyword>
	<keyword>Diffusion MRI</keyword>
</DOC>